Biocytogen’s ‘Nano 100 Project’ Aims to Develop Over 100 Fully Human Nanobody Drugs
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,”...
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,”...
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an antibody collaboration, assignment, and exclusive license...
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an evaluation and option agreement with Swiss...
Biocytogen (Beijing) Co., Ltd has announced the successful research and development of a fully-human nano...
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...
China-based Contract Research Organization (CRO) Biocytogen (Beijing) Co., Ltd has entered into a collaboration with...
China-based Biocytogen (Beijing) Co., Ltd and US-based Tracon Pharmaceuticals Inc. (Nasdaq: TCON) announced that the...
Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has entered into a global...
Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has completed an initial public...
Eucure Biopharma, a subsidiary of Sino-US contract research organization Biocytogen, announced that the first patient...